secwatch.observer — SEC 8-K summary
======================================

Issuer:     Grace Therapeutics, Inc. (GRCE)
CIK:        0001444192
Form:       8-K
Filed at:   2026-06-05T20:09:22+00:00
Accession:  0001140361-26-024269
Event type: leadership
Sentiment:  neutral
Materiality: 0.45
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Grace Therapeutics VP of Clinical Ops departing, will consult at $250/hr for NDA work
--------------------------------------------------------------------------------

- Carrie D'Andrea, VP of Clinical Operations, to cease employment effective June 5, 2026.
- She entered a 12-month consulting agreement at $250/hour for clinical development and NDA-related services.
- Stock option awards will continue to vest during the consulting term and remain exercisable for 90 days after termination.
- Severance benefits per November 2025 letter agreement, conditioned on release of claims and non-compete/non-solicitation covenants.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1444192/000114036126024269/0001140361-26-024269-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1444192/000114036126024269/ef20075612_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-024269

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer